Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.72 |
| ▸ | GAA | P10253 | 3/20 | 0.69 |
| ▸ | HTT | P42858 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | GFER | P55789 | 1/20 | 0.69 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22521844 | 0.85 | ADORA2A (0.77) | ADORA2AGAAHTTLMNAGFER | |
| SCHEMBL21175860 | 0.82 | GAA (1.00) | ADORA2AGAAHTTLMNAGFER | |
| SCHEMBL24559111 | 0.82 | ALOX15 (0.63) | ADORA2AGAAHTTLMNAGFER | |
| SCHEMBL24559321 | 0.77 | GAA (0.79) | ADORA2AGAAHTTLMNAGFER | |
| SCHEMBL21186474 | 0.76 | GAA (1.00) | ADORA2AGAAHTTLMNAGFER | |
| SCHEMBL16029010 | 0.76 | MAOA (0.54) | ADORA2AADORA3ADORA2BADORA1MAOA | |
| SCHEMBL7395584 | 0.75 | MAOA (0.54) | MAOAMAOB | |
| SCHEMBL7395581 | 0.75 | MAOA (0.54) | MAOAMAOB | |
| SCHEMBL21186476 | 0.73 | GAA (0.75) | ADORA2AGAAHTTLMNAGFER | |
| SCHEMBL25090499 | 0.70 | KDM4E (0.55) | ADORA2AADORA3ADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11203598-B2 | Compounds for repressing cancer cell growth | INSTITUTE FOR CANCER RESEARCH (US) | 2021-12-21 | — | — | US | disclosed |
| US-20190225613-A1 | Compounds For Repressing Cancer Cell Growth | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER | 2019-07-25 | — | — | US | disclosed |
| EP-2970316-B1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES INC (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-2970316-B1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES INC (US) | 2017-11-08 | — | — | EP | disclosed |
| US-20160145257-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. | 2016-05-26 | — | — | US | disclosed |
| US-20160145257-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. | 2016-05-26 | — | — | US | disclosed |
| WO-2014152287-A9 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
| WO-2014152287-A2 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140275528-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275528-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11203598-B2 | Compounds for repressing cancer cell growth | TP53, HRAS, RB1 | ADORA2A 1560/4885GAA 4560/4885HTT 1888/4885 |
| US-20160145257-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | ADORA2A 486/4885GAA 2882/4885HTT 1025/4885 |
| US-20140275528-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | ADORA2A 486/4885GAA 2882/4885HTT 1025/4885 |
| US-20190225613-A1 | Compounds For Repressing Cancer Cell Growth | TP53, MYC, HRAS | ADORA2A 3621/4885GAA 2749/4885HTT 3135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.